TAME is the most significant longevity trial currently running. What the trial design means, what a positive result would and would not prove, and what interim signals look like.
TAME — Targeting Aging with Metformin — is not a cardiovascular trial, a diabetes trial, or a cancer trial. It is a trial where aging itself is the target.
That distinction matters enormously. The FDA does not currently recognize aging as an indication — meaning no drug can be approved to treat aging per se. TAME was designed with an IND (Investigational New Drug application) that frames the target as the biology of aging, with a composite of age-related diseases as the measurable endpoint. If TAME succeeds, it will establish proof of concept that a drug can be approved to delay aging-related disease across the board — opening a regulatory pathway that does not currently exist.
That regulatory and scientific significance is independent of whether metformin itself shows benefit. TAME is as much about establishing a framework as it is about any single drug.
TAME enrolls 3,000 adults aged 65–79 who have one or more age-related conditions or risk factors (but not all of the conditions being studied). Participants are randomized to metformin 1500mg daily or placebo and followed for up to six years.
The composite endpoint design is deliberate. By measuring the first occurrence of any of these age-related conditions, TAME is testing whether metformin delays the aging process broadly — not whether it prevents any single disease. This is mechanistically coherent with the hypothesis: if AMPK activation and mTOR suppression slow cellular aging, the effect should appear across multiple disease endpoints simultaneously.
A positive TAME result — meaning metformin significantly delays the composite endpoint — would mean several things simultaneously.
First, it would provide the first Phase III randomised controlled trial evidence that a pharmacological intervention can delay multiple age-related diseases in healthy older adults. That would move metformin from Moderate to Strong on the Geroevidence evidence ladder immediately.
Second, it would validate the aging-as-indication regulatory framework, potentially opening the door for other longevity drugs to pursue the same approval pathway.
What it would not mean: that metformin extends maximum lifespan, that the benefit applies to populations under 65, or that other AMPK activators or mTOR inhibitors would necessarily show the same benefit. The trial is in older adults with existing age-related risk factors — extrapolation to younger healthy populations would require additional evidence.
A negative result would not necessarily mean metformin has no longevity benefit. It would mean that at the dose tested, in the population enrolled, over the follow-up period studied, metformin did not significantly delay the composite endpoint.
The trial is powered for a clinically meaningful effect size. A smaller benefit — below the statistical threshold — would not be detected. A negative result would, however, significantly dampen enthusiasm for off-label metformin prescribing in healthy aging adults and would set back the aging-as-indication regulatory framework considerably.
TAME is expected to complete follow-up in 2028 with results anticipated in 2028–2029. Interim analyses are scheduled but specific thresholds have not been publicly disclosed.
Conference presentations from the TAME investigators have indicated that enrollment has proceeded on schedule and that no safety signals have emerged requiring protocol modification. No efficacy data has been disclosed from interim analyses. Geroevidence will update this profile immediately upon any interim or final data release.